US90400D1081 - RARE - A1XCY0 (XNAS)
ULTRAGENYX PHARMACEUTICAL INC Aktie
58,78 USD
Aktuelle Kurse von ULTRAGENYX PHARMACEUTICAL INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
RARE
|
USD
|
19.09.2024 23:02
|
58,78 USD
| 57,70 USD | 1,87 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -1,13 % | 9,77 % | 57,08 % | 25,06 % | 61,53 % | 35,53 % |
Firmenprofil zu ULTRAGENYX PHARMACEUTICAL INC Aktie
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Investierte Fonds
Folgende Fonds haben in ULTRAGENYX PHARMACEUTICAL INC investiert:
Fonds | Vol. in Mio 226,68 | Anteil (%) 0,53 % |
Unternehmensdaten zur ULTRAGENYX PHARMACEUTICAL INC Aktie
Name ULTRAGENYX PHARMACEUTICAL INC
Firma Ultragenyx Pharmaceutical Inc.
Symbol RARE
Website https://www.ultragenyx.com
Heimatbörse
NASDAQ
WKN A1XCY0
ISIN US90400D1081
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Emil D. Kakkis M.D., Ph.D.
Marktkapitalisierung 5 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 1,3 T
Adresse 60 Leveroni Court, 94949 Novato
IPO Datum 2014-01-31
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | UP0.F |
NASDAQ | RARE |
Weitere Aktien
Investoren die ULTRAGENYX PHARMACEUTICAL INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024